Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas

Susannah Yovino, Stuart A Grossman

Research output: Contribution to journalReview article

Abstract

Lymphopenia is a common consequence of therapy for malignant glioma. Current standard therapy includes corticosteroids, temozolomide and radiation therapy, all of which are toxic to lymphocytes. The resulting immunosuppression has serious clinical consequences. Decreased lymphocyte counts can result in opportunistic infections, decreased efficacy of immunotherapy and reduced overall survival. The exact mechanisms underlying the association between decreased survival and lymphopenia in malignant glioma patients are unclear. However, as lymphocytes are key effector cells in the immune response to cancer, it is likely that depleting their numbers renders the immune system less effective at eliminating malignant cells. Currently, no strategies exist for the prevention or reversal of treatment-related immunosuppression in malignant glioma patients, although there are several promising theoretical approaches. This article reviews the current state of knowledge regarding the severity, etiology and possible consequences of treatment-related lymphopenia in patients with malignant glioma.

Original languageEnglish (US)
Pages (from-to)149-154
Number of pages6
JournalCNS oncology
Volume1
Issue number2
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Lymphopenia
Glioma
temozolomide
Immunosuppression
Lymphocytes
Survival
Poisons
Opportunistic Infections
Lymphocyte Count
Therapeutics
Immunotherapy
Immune System
Adrenal Cortex Hormones
Radiotherapy
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. / Yovino, Susannah; Grossman, Stuart A.

In: CNS oncology, Vol. 1, No. 2, 01.11.2012, p. 149-154.

Research output: Contribution to journalReview article

@article{72a6389a8d7a473a9d92cca44bdfebd2,
title = "Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas",
abstract = "Lymphopenia is a common consequence of therapy for malignant glioma. Current standard therapy includes corticosteroids, temozolomide and radiation therapy, all of which are toxic to lymphocytes. The resulting immunosuppression has serious clinical consequences. Decreased lymphocyte counts can result in opportunistic infections, decreased efficacy of immunotherapy and reduced overall survival. The exact mechanisms underlying the association between decreased survival and lymphopenia in malignant glioma patients are unclear. However, as lymphocytes are key effector cells in the immune response to cancer, it is likely that depleting their numbers renders the immune system less effective at eliminating malignant cells. Currently, no strategies exist for the prevention or reversal of treatment-related immunosuppression in malignant glioma patients, although there are several promising theoretical approaches. This article reviews the current state of knowledge regarding the severity, etiology and possible consequences of treatment-related lymphopenia in patients with malignant glioma.",
author = "Susannah Yovino and Grossman, {Stuart A}",
year = "2012",
month = "11",
day = "1",
language = "English (US)",
volume = "1",
pages = "149--154",
journal = "CNS oncology",
issn = "2045-0915",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas

AU - Yovino, Susannah

AU - Grossman, Stuart A

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Lymphopenia is a common consequence of therapy for malignant glioma. Current standard therapy includes corticosteroids, temozolomide and radiation therapy, all of which are toxic to lymphocytes. The resulting immunosuppression has serious clinical consequences. Decreased lymphocyte counts can result in opportunistic infections, decreased efficacy of immunotherapy and reduced overall survival. The exact mechanisms underlying the association between decreased survival and lymphopenia in malignant glioma patients are unclear. However, as lymphocytes are key effector cells in the immune response to cancer, it is likely that depleting their numbers renders the immune system less effective at eliminating malignant cells. Currently, no strategies exist for the prevention or reversal of treatment-related immunosuppression in malignant glioma patients, although there are several promising theoretical approaches. This article reviews the current state of knowledge regarding the severity, etiology and possible consequences of treatment-related lymphopenia in patients with malignant glioma.

AB - Lymphopenia is a common consequence of therapy for malignant glioma. Current standard therapy includes corticosteroids, temozolomide and radiation therapy, all of which are toxic to lymphocytes. The resulting immunosuppression has serious clinical consequences. Decreased lymphocyte counts can result in opportunistic infections, decreased efficacy of immunotherapy and reduced overall survival. The exact mechanisms underlying the association between decreased survival and lymphopenia in malignant glioma patients are unclear. However, as lymphocytes are key effector cells in the immune response to cancer, it is likely that depleting their numbers renders the immune system less effective at eliminating malignant cells. Currently, no strategies exist for the prevention or reversal of treatment-related immunosuppression in malignant glioma patients, although there are several promising theoretical approaches. This article reviews the current state of knowledge regarding the severity, etiology and possible consequences of treatment-related lymphopenia in patients with malignant glioma.

UR - http://www.scopus.com/inward/record.url?scp=84990879008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990879008&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 149

EP - 154

JO - CNS oncology

JF - CNS oncology

SN - 2045-0915

IS - 2

ER -